DRAVP ID  DRAVPe01722

Peptide Name   P1(SARS-CoV (1153-1189))

Sequence  GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE

Sequence Length  37

UniProt ID  P59594 

Source  Synthetic construct

Target Organism  SARS-CoV

Assay  cell fusion inhibition assay

Activity 

• [Ref.18983873]SARS-CoV:inhibition of cell fusion in Hela cells (IC50=0.62 ± 0.20 μM);inhibition of SARS-CoV infection in Vero-E6 cells (IC50=3.04 ± 0.06 μM).
• [Ref.15043961]SARS-CoV:inhibition of the cytopathic effect in Vero E6 cells(IC50~19 μM/L).

Hemolytic Activity  No hemolysis information or data found in the reference(s) presented in this entry

Cytotoxicity 

• [Ref.18983873]No discernable cytotoxicity on HeLa or VeroE6 cells at the concentrations of 25 μM.

Binding Target  membrane

Mechanism  Binding to the HR1 region and blocking the formation of a 6-helix bundle during the fusion step of virus entry, thus inhibiting virus entry.

PDB ID  None

Predicted Structure Download  No predicted structure available

Linear/Cyclic  Linear

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Stereochemistry  L

Literature 1

Title   Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors.

Pubmed ID   18983873

Reference   Antiviral Res. 2009 Jan;81(1):82-7.

Author   Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, Wang WK.

DOI   10.1093/infdis/jiv325.

Literature 2

Title   Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.

Pubmed ID   15043961

Reference   Lancet. 2004 Mar 20;363(9413):938-47.

Author   Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante CR, Xiong H, Farmar J, Debnath AK, Tien P, Jiang S.

DOI   10.1016/j.antiviral.2008.10.001.